Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jobelyn in breast cancer
NCT01936064Phase 2
Key facts
- Status
- Unknown
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Countries
- 1
- Sponsor
- Lagos State University
- Modality
- Small Molecules
- Drugs
- jobelyn
- Conditions
- breast cancer
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Jobelyn + Cyclophosphamide-Epirubicin with Placebo + Cyclophosphamide-Epirubicin (2 arms). Primary endpoint: Natural Killer Cells Expression (Cluster of Differentiation 69) at 6 months. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Jobelyn + Cyclophosphamide-Epirubicin
Jobelyn + Cyclophosphamide-Epirubicin
Placebo + Cyclophosphamide-Epirubicin
Placebo + Cyclophosphamide-Epirubicin
03
Who it enrols
Women with histologically confirmed breast cancer who had undergone complete or segmental mastectomy plus axillary node dissection.
04
Endpoints
Primary
Natural Killer Cells Expression (Cluster of Differentiation 69)
Secondary
Safety Fractor-36 Health Survey
Hematocrit Changes
Beyond the preview
Go deeper on NCT01936064.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01936064.